August 2012
-
Inhaled drug developer Aerami Therapeutics has announced that it will go public through a merger with a special purpose acquisition company (SPAC) called FoxWayne Enterprises Acquisition Corp., and the resulting company’s common stock will be… Read more . . .
-
The Cystic Fibrosis Foundation announced that it is providing $3.5 million for a Phase 2 study of Pulmocide Ltd’s PC945 inhaled opelconazole for the prevention of pulmonary Aspergillus infections following lung transplantation. The CF Foundation noted… Read more . . .
-
Biohaven Pharmaceutical said that a Phase 3 trial of its intranasal zavegepant (BHV-3500) for the treatment of moderate or severe migraine has met its primary endpoints, demonstrating statistically significant increase in freedom from both pain and… Read more . . .
-
Lupin announced that it has acquired exclusive global rights to soft mist inhalation technology developed by Cambridge, UK design company TTP, and the two companies will co-develop the SMI device for delivery of inhaled drugs.… Read more . . .
-
Inhaled nitric oxide developer Beyond Air announced that pulmonologist Andrew Colin has been appointed as the company’s Chief Medical Officer, effective December 1, 2021. Colin, who was most recently Chief of the Division of Pediatric… Read more . . .
-
Canadian pharma company Pharmascience has announced that it will stop manufacturing pms-sodium cromoglycate inhalation solution due to a 95% drop in demand over the past 15 years. Pharmascience now says it will sell pms-sodium cromoglycate… Read more . . .
-
By the ISAM board of directors As scientific leaders during a respiratory pandemic, the International Society for Aerosols in Medicine (ISAM) has been very busy over the past year, working to advance the understanding of… Read more . . .
-
Following the lifting of government restrictions related to the COVID-19 pandemic, device design and development company Team Consulting is once again welcoming visitors to its headquarters in Cambridge, UK. Team has recently opened a new… Read more . . .
-
The FDA has approved Alembic Pharmaceuticals’ ANDA for its formoterol fumarate inhalation solution, a generic of Mylan’s Perforomist inhalation solution for the treatment of COPD, the company said. According to the announcement, this is the… Read more . . .
-
Janssen Pharmaceutical announced that it has launched Spravato esketamine nasal spray in Australia for the treatment of treatment-resistant depression following approval by the TGA. The company also said that will file a submission to the… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.